Novartis licenses ophthalmology gene therapy from Spark Therapeutics – Zenopa
Zacks.com |
Novartis licenses ophthalmology gene therapy from Spark Therapeutics
Zenopa Novartis has agreed an exclusive licensing deal for an innovative ophthalmology gene therapy from Spark Therapeutics. The deal covers development, registration and commercialisation rights to voretigene neparvovec – which is sold in the US under the … Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & More Novartis Gets Spark Therapeutics' Luxterna License Outside US |
